Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PFIZER INC Earnings Release 2014

Jan 28, 2014

29831_rns_2014-01-28_def25e09-baf2-4042-8753-0771e77d27b5.zip

Earnings Release

Open in viewer

Opens in your device viewer

8-K 1 pfe-12312013x8k.htm 8-K html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" Document created using WebFilings 1 Copyright 2008-2014 WebFilings LLC. All Rights Reserved PFE-12.31.2013-8K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 28, 2014

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware 1-3619 13-5315170
(State or other (Commission File (I.R.S. Employer
jurisdiction of (Number) Identification No.)
incorporation)
235 East 42nd Street 10017
New York, New York (Zip Code)

(Address of principal executive offices)

Registrant's telephone number, including area code:

(212) 733-2323

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On January 28, 2014, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the fourth-quarter and full-year 2013. The information contained in the press release is deemed to be “filed” under the Securities Exchange Act of 1934 as Exhibit 99 to this report, and such press release is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit 99 - Press Release of Pfizer Inc. dated January 28, 2014, reporting Pfizer's financial results for the fourth-quarter and full-year 2013. Exhibit 99 is deemed to be “filed” under the Securities Exchange Act of 1934 in this Current Report on Form 8-K.

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

By: /s/ Douglas M. Lankler
Douglas M. Lankler
Executive Vice President, General Counsel and Corporate Secretary
Dated: January 28, 2014

EXHIBIT INDEX

Exhibit No. Description
99 Press Release of Pfizer Inc. dated
January 28, 2014, reporting Pfizer's financial
results for the fourth-quarter and full-year 2013.